Organon (Organon) Other Current Payables : $0 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Organon Other Current Payables?

Organon's Other Current Payables for the quarter that ended in Dec. 2023 was $0 Mil.

Organon Other Current Payables Historical Data

The historical data trend for Organon's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Other Current Payables Chart

Organon Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

Organon Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Current Payables	Get a 7-Day Free Trial													-	-	-	-	-

Organon Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Organon Other Current Payables Related Terms

Thank you for viewing the detailed overview of Organon's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Organon (Organon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

OGN:Mexico 1OGN:Italy 0A9W:UK 7XP:Germany

Address

30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302

Website

https://www.organon.com

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.

Executives

Kirke Weaver	officer: Gen. Counsel & Corp. Secy.	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco	director	ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman	officer: General Counsel	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco	officer: Corporate Controller	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler	officer: Chief Commercial Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita	officer: Head of Global Business Svcs	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr.	officer: Head of Manufacturing	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione	officer: Chief Human Resources Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah	director	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter	officer: Hd of Ext. Affairs and ESG	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan	officer: Head of Research & Development	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139